New perspectives of immunosuppression

F. Halleck, F. Friedersdorff, T. F. Fuller, M. Matz, Lu Yu Huber, M. Dürr, M. Schütz, K. Budde

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Efficient rejection prophylaxis and excellent short-term results in organ transplantation can not obscure the fact that long-term outcomes have not improved substantially over the last decade with rather constant graft attrition rates beyond the first year. There remains an unmet medical need for new immunosuppressive regimens to improve long-term graft and patient survival while carrying a low side effect burden. Several trials in renal transplant recipients are in the planning stages. In general there are two major strategies to improve outcomes: (a) the constant evolution of new immunosuppressive regimens with the currently approved immunosuppressants, and/or (b) the use of novel immunosuppressants. In this review, we give an overview of the most recent developments of novel immunosuppressive regimes. We show promising new immunosuppressive drugs and new immunosuppressive strategies serving as potential alternative's for calcineurin inhibitor-based regimens. Such regimens should provide similar efficacy and eventually better tolerability or a different side-effect profile with clinical benefits.

Original languageEnglish (US)
Pages (from-to)1224-1231
Number of pages8
JournalTransplantation Proceedings
Volume45
Issue number3
DOIs
StatePublished - Apr 1 2013

Fingerprint

Immunosuppressive Agents
Immunosuppression
Organ Transplantation
Graft Survival
Transplants
Kidney
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Halleck, F., Friedersdorff, F., Fuller, T. F., Matz, M., Huber, L. Y., Dürr, M., ... Budde, K. (2013). New perspectives of immunosuppression. Transplantation Proceedings, 45(3), 1224-1231. https://doi.org/10.1016/j.transproceed.2013.02.033

New perspectives of immunosuppression. / Halleck, F.; Friedersdorff, F.; Fuller, T. F.; Matz, M.; Huber, Lu Yu; Dürr, M.; Schütz, M.; Budde, K.

In: Transplantation Proceedings, Vol. 45, No. 3, 01.04.2013, p. 1224-1231.

Research output: Contribution to journalArticle

Halleck, F, Friedersdorff, F, Fuller, TF, Matz, M, Huber, LY, Dürr, M, Schütz, M & Budde, K 2013, 'New perspectives of immunosuppression', Transplantation Proceedings, vol. 45, no. 3, pp. 1224-1231. https://doi.org/10.1016/j.transproceed.2013.02.033
Halleck F, Friedersdorff F, Fuller TF, Matz M, Huber LY, Dürr M et al. New perspectives of immunosuppression. Transplantation Proceedings. 2013 Apr 1;45(3):1224-1231. https://doi.org/10.1016/j.transproceed.2013.02.033
Halleck, F. ; Friedersdorff, F. ; Fuller, T. F. ; Matz, M. ; Huber, Lu Yu ; Dürr, M. ; Schütz, M. ; Budde, K. / New perspectives of immunosuppression. In: Transplantation Proceedings. 2013 ; Vol. 45, No. 3. pp. 1224-1231.
@article{dfa875f439184797a79d0d8e71d95daf,
title = "New perspectives of immunosuppression",
abstract = "Efficient rejection prophylaxis and excellent short-term results in organ transplantation can not obscure the fact that long-term outcomes have not improved substantially over the last decade with rather constant graft attrition rates beyond the first year. There remains an unmet medical need for new immunosuppressive regimens to improve long-term graft and patient survival while carrying a low side effect burden. Several trials in renal transplant recipients are in the planning stages. In general there are two major strategies to improve outcomes: (a) the constant evolution of new immunosuppressive regimens with the currently approved immunosuppressants, and/or (b) the use of novel immunosuppressants. In this review, we give an overview of the most recent developments of novel immunosuppressive regimes. We show promising new immunosuppressive drugs and new immunosuppressive strategies serving as potential alternative's for calcineurin inhibitor-based regimens. Such regimens should provide similar efficacy and eventually better tolerability or a different side-effect profile with clinical benefits.",
author = "F. Halleck and F. Friedersdorff and Fuller, {T. F.} and M. Matz and Huber, {Lu Yu} and M. D{\"u}rr and M. Sch{\"u}tz and K. Budde",
year = "2013",
month = "4",
day = "1",
doi = "10.1016/j.transproceed.2013.02.033",
language = "English (US)",
volume = "45",
pages = "1224--1231",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - New perspectives of immunosuppression

AU - Halleck, F.

AU - Friedersdorff, F.

AU - Fuller, T. F.

AU - Matz, M.

AU - Huber, Lu Yu

AU - Dürr, M.

AU - Schütz, M.

AU - Budde, K.

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Efficient rejection prophylaxis and excellent short-term results in organ transplantation can not obscure the fact that long-term outcomes have not improved substantially over the last decade with rather constant graft attrition rates beyond the first year. There remains an unmet medical need for new immunosuppressive regimens to improve long-term graft and patient survival while carrying a low side effect burden. Several trials in renal transplant recipients are in the planning stages. In general there are two major strategies to improve outcomes: (a) the constant evolution of new immunosuppressive regimens with the currently approved immunosuppressants, and/or (b) the use of novel immunosuppressants. In this review, we give an overview of the most recent developments of novel immunosuppressive regimes. We show promising new immunosuppressive drugs and new immunosuppressive strategies serving as potential alternative's for calcineurin inhibitor-based regimens. Such regimens should provide similar efficacy and eventually better tolerability or a different side-effect profile with clinical benefits.

AB - Efficient rejection prophylaxis and excellent short-term results in organ transplantation can not obscure the fact that long-term outcomes have not improved substantially over the last decade with rather constant graft attrition rates beyond the first year. There remains an unmet medical need for new immunosuppressive regimens to improve long-term graft and patient survival while carrying a low side effect burden. Several trials in renal transplant recipients are in the planning stages. In general there are two major strategies to improve outcomes: (a) the constant evolution of new immunosuppressive regimens with the currently approved immunosuppressants, and/or (b) the use of novel immunosuppressants. In this review, we give an overview of the most recent developments of novel immunosuppressive regimes. We show promising new immunosuppressive drugs and new immunosuppressive strategies serving as potential alternative's for calcineurin inhibitor-based regimens. Such regimens should provide similar efficacy and eventually better tolerability or a different side-effect profile with clinical benefits.

UR - http://www.scopus.com/inward/record.url?scp=84876873067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876873067&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2013.02.033

DO - 10.1016/j.transproceed.2013.02.033

M3 - Article

VL - 45

SP - 1224

EP - 1231

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 3

ER -